in the absence of a submission from the holder of the marketing authorisation
panitumumab (Vectibix®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients with wild-type RAS metastatic colorectal cancer first-line in combination with FOLFIRI.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of panitumumab in this indication. However, due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued.
Download detailed advice110KB (PDF)
- Medicine name:
- panitumumab (Vectibix)
- SMC ID:
- Treatment of adult patients with wild-type RAS metastatic colorectal cancer first-line in combination with FOLFIRI.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Date advice published:
- 13 July 2015